

Here for You. Built for Rheumatology.



AMERICAN COLLEGE
of RHEUMATOLOGY
Empowering Rheumatology Professionals

The Advancing Rheumatology Patient Care MIPS Value Pathway (MVP) Quality Measures Informational Guide

[MIPS Value Pathways \(MVPs\)](#) are the newest reporting option to fulfill MIPS reporting requirements starting in 2023, and they are designed as a subset of measures and activities for subspecialty care. With MVPs there is a foundational layer calculated through promoting interoperability and population health measures and additional performance across three categories: quality, improvement activities, and cost. The Centers for Medicaid and Medicare Services (CMS) have signaled an intent to sunset [Traditional MIPS](#) and require MVP participation in the future but has not provided a date for this transition.

The [Advancing Rheumatology Patient Care MVP](#) focuses on the clinical theme of providing fundamental treatment and management of rheumatological conditions. Below is a summary of the quality measures available for MIPS reporting via the Advancing Rheumatology Patient Care MVP for the 2024 performance year (Jan 1, 2024–Dec 31, 2024). Additional information on CMS requirements for both Traditional MIPS and MVPs is available on the [QPP website](#).

Measure Title	Type of Measure	Has a Benchmark?	Topped Out
QPP130: Documentation of Current Medications in the Medical Record	Process: High priority measure	Yes	Yes
QPP134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan	Process	Yes [CQM] No [eCQM]	Yes [CQM] N/A [eCQM]
QPP176: Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy	Process	Yes	Yes
QPP177: Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	Process	Yes	Yes
QPP178: Rheumatoid Arthritis (RA): Functional Status Assessment	Process	Yes	Yes
QPP180: Rheumatoid Arthritis (RA): Glucocorticoid Management	Process	Yes	Yes
QPP487: Screening for Social Drivers of Health	Process: High priority measure	No	N/A
QPP493: Adult Immunization Status	Process	No	N/A
QPP503: Gains in Patient Activation Measure Scores at 12 Months	Outcome: High priority measure	No	N/A
*ACR12: Disease Activity Measurement for Patients with PsA	Process	Yes	No
*ACR14: Gout: Serum Urate Target	Outcome: High priority measure	Yes	No
*ACR15: Safe Hydroxychloroquine Dosing	Process: High priority measure	Yes	No

* These ACR-owned, rheumatology specific QCDR measures are exclusive to the RISE registry and only available through RISE for reporting.